摘要
目的探究比索洛尔联合阿托伐他汀治疗稳定型心绞痛(SAP)患者的疗效。方法回顾收集我院2018年1月至2020年12月入院治疗的448例SAP患者的临床资料,按照治疗方案不同分组,224例采用阿托伐他汀治疗为对照组,224例采用比索洛尔联合阿托伐他汀治疗为观察组,比较两组疗效、治疗前后心绞痛发作频率、持续时间、心功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)]、肱动脉血流介导内皮舒张功能(FMD)、颗粒膜蛋白-140(GMP140)水平及不良反应发生率。结果观察组总有效率(93.30%)较对照组(78.13%)高(p<0.05);治疗后观察组心绞痛发作频率较对照组低,持续时间较对照组短(p<0.05);治疗后观察组LVEF较对照组高,LVESD、LVEDD较对照组低(p<0.05);治疗后观察组FMD较对照组高,GMP140较对照组低(p<0.05);两组患者不良反应发生率比较无明显差异(p>0.05)。结论比索洛尔联合阿托伐他汀治疗SAP患者效果显著,可有效控制心绞痛发作,提高心功能,抑制动脉粥样硬化进程,且安全性较高。
Objective To explore the curative effect of bisoprolol combined with atorvastatin on patients with stable angina pectoris(SAP). Methods The clinical data of 448 SAP patients admitted to our hospital from January 2018 to December 2020 were collected retrospectively. According to different treatment schemes, 224 patients were treated with atorvastatin as control group and 224 patients were treated with bisoprolol combined with atorvastatin as observation group. The efficacy, frequency and duration of angina pectoris, heart function [left ventricular ejection fraction(LVEF), left ventricular end-diastolic diameter(LVEDD), left ventricular end-systolic diameter(LVESD)], brachial artery blood flow-mediated endothelial diastolic function(FMD), granular membrane protein-140(GMP140) and the incidence of adverse reactions were compared between the two groups before and after treatment. Results The total effective rate of the observation group was 93.30% higher than that of the control group(78.13%, p <0.05). After treatment, the frequency and duration of angina pectoris in observation group were lower than those in control group(p<0.05). After treatment, LVEF in observation group was higher than that in control group, and LVESD and LVEDD were lower than those in control group(p <0.05). After treatment, FMD and GMP140 in observation group were higher than those in control group(p<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(p >0.05). Conclusions Bisoprolol combined with atorvastatin is effective in the treatment of SAP patients, which can effectively control angina pectoris, improve heart function and inhibit the progression of atherosclerosis, and has high safety.
作者
张玉
王勇
许学升
Zhang yu;Wang yong;Xu xuesheng(The First People's Hospital of Shangqiu City,Henan Province,476000,China)
出处
《临床心电学杂志》
2021年第5期369-372,共4页
Journal of Clinical Electrocardiology
